Gilead Sciences Ltd. (JOBS) Deepens Roots in Seattle, Seeks Long-Term Payoff From Lung Disease Research
Xconomy.com -- Gilead Sciences spent $365 million to get a toehold in Seattle back in 2006, and so far, it has zero U.S. product sales to show for it. That’s made investors antsy, but it hasn’t deterred the world’s second-most valuable biotech company from continuing to bet big on Seattle as part of its plan to diversify away from its heavy reliance on HIV medications.